Dextromethorphan reduces neocortical ischemic neuronal damage in vivo

Charles P. George, Mark P. Goldberg, Dennis W. Choi, Gary K. Steinberg

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

The dextrorotatory morphinan dextromethorphan (DM), a clinically tested antagonist of the N-methyl-d-aspartate (NMDA) receptor-channel complex, was tested in an in vivo model of acute transient focal cerebral ischemia. Rabbits were randomly assigned to pretreatment with a 20 mg/kg i.v. bolus followed by 10 mg/kg/h of 0.4% DM in normal saline (NS), or with an equivalent volume of NS alone. They then underwent 1 h occlusion of the left internal carotid artery and anterior cerebral artery followed by 4 h of reperfusion. DM-treated animals showed a significant decrease in the percentage of severe neocortical ischemic neuronal damage (10.5%), as compared to NS-treated animals (49.6%).

Original languageEnglish (US)
Pages (from-to)375-379
Number of pages5
JournalBrain Research
Volume440
Issue number2
DOIs
StatePublished - Feb 9 1988

Fingerprint

Dextromethorphan
Morphinans
Anterior Cerebral Artery
Transient Ischemic Attack
Internal Carotid Artery
Reperfusion
Rabbits

Keywords

  • Dextromethorphan
  • Ischemia
  • N-methyl-d-aspartic acid (NMDA)
  • Neocortex
  • Striatum

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. / George, Charles P.; Goldberg, Mark P.; Choi, Dennis W.; Steinberg, Gary K.

In: Brain Research, Vol. 440, No. 2, 09.02.1988, p. 375-379.

Research output: Contribution to journalArticle

George, Charles P. ; Goldberg, Mark P. ; Choi, Dennis W. ; Steinberg, Gary K. / Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. In: Brain Research. 1988 ; Vol. 440, No. 2. pp. 375-379.
@article{c87de91523744ed08dca322c61aa8e9d,
title = "Dextromethorphan reduces neocortical ischemic neuronal damage in vivo",
abstract = "The dextrorotatory morphinan dextromethorphan (DM), a clinically tested antagonist of the N-methyl-d-aspartate (NMDA) receptor-channel complex, was tested in an in vivo model of acute transient focal cerebral ischemia. Rabbits were randomly assigned to pretreatment with a 20 mg/kg i.v. bolus followed by 10 mg/kg/h of 0.4{\%} DM in normal saline (NS), or with an equivalent volume of NS alone. They then underwent 1 h occlusion of the left internal carotid artery and anterior cerebral artery followed by 4 h of reperfusion. DM-treated animals showed a significant decrease in the percentage of severe neocortical ischemic neuronal damage (10.5{\%}), as compared to NS-treated animals (49.6{\%}).",
keywords = "Dextromethorphan, Ischemia, N-methyl-d-aspartic acid (NMDA), Neocortex, Striatum",
author = "George, {Charles P.} and Goldberg, {Mark P.} and Choi, {Dennis W.} and Steinberg, {Gary K.}",
year = "1988",
month = "2",
day = "9",
doi = "10.1016/0006-8993(88)91011-6",
language = "English (US)",
volume = "440",
pages = "375--379",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Dextromethorphan reduces neocortical ischemic neuronal damage in vivo

AU - George, Charles P.

AU - Goldberg, Mark P.

AU - Choi, Dennis W.

AU - Steinberg, Gary K.

PY - 1988/2/9

Y1 - 1988/2/9

N2 - The dextrorotatory morphinan dextromethorphan (DM), a clinically tested antagonist of the N-methyl-d-aspartate (NMDA) receptor-channel complex, was tested in an in vivo model of acute transient focal cerebral ischemia. Rabbits were randomly assigned to pretreatment with a 20 mg/kg i.v. bolus followed by 10 mg/kg/h of 0.4% DM in normal saline (NS), or with an equivalent volume of NS alone. They then underwent 1 h occlusion of the left internal carotid artery and anterior cerebral artery followed by 4 h of reperfusion. DM-treated animals showed a significant decrease in the percentage of severe neocortical ischemic neuronal damage (10.5%), as compared to NS-treated animals (49.6%).

AB - The dextrorotatory morphinan dextromethorphan (DM), a clinically tested antagonist of the N-methyl-d-aspartate (NMDA) receptor-channel complex, was tested in an in vivo model of acute transient focal cerebral ischemia. Rabbits were randomly assigned to pretreatment with a 20 mg/kg i.v. bolus followed by 10 mg/kg/h of 0.4% DM in normal saline (NS), or with an equivalent volume of NS alone. They then underwent 1 h occlusion of the left internal carotid artery and anterior cerebral artery followed by 4 h of reperfusion. DM-treated animals showed a significant decrease in the percentage of severe neocortical ischemic neuronal damage (10.5%), as compared to NS-treated animals (49.6%).

KW - Dextromethorphan

KW - Ischemia

KW - N-methyl-d-aspartic acid (NMDA)

KW - Neocortex

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=0023830112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023830112&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(88)91011-6

DO - 10.1016/0006-8993(88)91011-6

M3 - Article

C2 - 3359222

AN - SCOPUS:0023830112

VL - 440

SP - 375

EP - 379

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -